Navigation Links
Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
Date:12/18/2007

SAN MARINO, Calif., Dec. 18 /PRNewswire/ -- Epeius Biotechnologies Corporation announced today their appreciation of the accomplishments of their contemporaries in 2007, a truly remarkable year in terms of biomedical research, scholarship, and gonzo journalism. It was a year in which a definitive meeting entitled "In Vivo Barriers to Gene Delivery" was held at the prestigious Cold Spring Harbor Laboratory, where Nobel laureate James Watson presides, or shall we say presided. The meeting served to inform the public and the scientific community that there were actual reasons that the much heralded promise of gene therapy had thus far failed to deliver. Perhaps, if the title of the meeting had been changed to "In Vivo Solutions to Gene Delivery," the scientists of Epeius Biotechnologies might have attended.

*(LOGO 72dpi: Send2Press.com/mediaboom/logo-epeius_72dpi.jpg)

2007 was a year that the 'experts' of all things targeted published a remarkable review article in Nature (Nature Reviews, Genetics, 2007, 8:573-587) entitled "Engineering Targeted Viral Vectors for Gene Therapy." Among the flotsam and jetsam of adenoviral shipwrecks, and the ruminative discourses on "Obstacles to Systemic Targeting," was an intriguing preface stating that "the first clinical trials have already begun to take place," and a brief notation that may be of considerable scientific interest. And we quote, "A third example is represented by the first and so far only targeted vector that has been tested in the clinic: the retroviral vector Rexin-G, which expresses a cytocidal dominant-negative form of cyclin G1." The article goes as far as to mention the fact that a number of clinical studies have "demonstrated the effectiveness of the vector" in the crucible of clinical medicine.

Ironically, 2007 is also the year in which the much acclaimed and heavily subsidized National Gene Vector Laboratories (NGVL) -- whose mission and "primary goal" as an academic vector production facility and national resource was ostensibly to provide clinical grade vectors for clinical gene transfer protocols -- has closed its doors and announced the discontinuance of its programs, while all the world wonders. This same year, 2007, is the year that Rexin-G(R), the world's first and so far only targeted injectable genetic medicine that was designed, engineered, manufactured, validated, tested, and approved for the treatment of otherwise intractable metastatic cancers; the first and so far only one of the plethora of targeted biologics that exhibits broad spectrum anti-cancer activity when administered as a single therapeutic agent, advances alone toward product registration worldwide. So it appears that those of our academic colleagues should continue to teach and tell, while those who can actually do, should continue to do just that.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its lead products and proprietary targeted delivery systems. Credited with innovations ranging from gene discovery, to designer therapeutic genes, to pathotropic (disease-seeking) targeting, to ultra high-performance vector engineering, to advanced biopharmaceutical manufacturing and bioprocess development, Epeius Biotechnologies is well positioned to "launch" its enabling platform technologies for the benefit of cancer patients worldwide. Meanwhile, rapid advances in clinical drug development provide Epeius with a unique opportunity for early revenues from the sale of its lead product to the Philippines and reciprocating ASEAN countries -- thus demonstrating the high growth potential of a small biotechnology company while maintaining the lowered risk profile of a biopharmaceutical company with a high-value, late-stage product.

More information: http://www.epeiusbiotech.com

Rexin-G is a U.S. registered trademark of Epeius Biotechnologies Corporation.

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com


'/>"/>
SOURCE Epeius Biotechnologies Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
2. Most Women With HIV and Their Health Care Providers Have Not Discussed How HIV Might Affect Them Differently Than Men
3. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
4. Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
5. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
6. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
7. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
8. Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
9. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
10. ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... founder of Echenberg Institute, is announcing a new safe and effective at-home ... and other painful pelvic pain conditions such as pelvic floor dysfunction, vulvodynia, ... ... ... start-up company, VuVatech LLC, fills a void in the women,s wellness market ...
(Date:7/10/2017)... , July 10, 2017  The tenth annual ... Boston, MA at the Sheraton Boston ... and unparalleled access to global decision makers and innovative ... 800+ life science leaders during two impactful days. BioPharm ... provides delegates with additional networking opportunities with 4,500+ life ...
Breaking Medicine Technology:
(Date:7/24/2017)... VA (PRWEB) , ... July 24, 2017 , ... ... Managers, **Presented by FDAnews and MSceppa Consulting **, Aug. 22-23, 2017 – Arlington, ... on Friday, July 28. , Increased FDA scrutiny and growing demands to track ...
(Date:7/24/2017)... ... July 24, 2017 , ... Advanced ... Avenue, Bellmore, New York, (516) 784-5858. The office opened earlier this summer and ... Lori Friedman and Fruma Leah Wiederman. , Advanced Dermatology, P.C. founder and ...
(Date:7/24/2017)... , ... July 24, 2017 , ... “A Short Walk ... to the Mailbox” is the creation of published author, Ed Clark. Ed Clark ... Methodist, and Christian Reformed churches as a minister of music and worship leader for ...
(Date:7/23/2017)... ... 2017 , ... Three experts will be interviewed on Facebook ... & Exhibition, to be held in Denver, CO on July 30-August 3, 2017. ... visit the AAPM Facebook page to watch three speakers present their information and ...
(Date:7/23/2017)... CA (PRWEB) , ... July 23, 2017 , ... ... indicating women who underwent brief bursts of high-intensity, weight-bearing activity equivalent to a medium-paced ... health. , “As an orthopaedic surgeon who specializes in total spine care, I understand ...
Breaking Medicine News(10 mins):